Literature DB >> 15877079

Tumour-suppression activity of the proapoptotic regulator Par4.

Isabel García-Cao1, Angeles Duran, Manuel Collado, Maria J Carrascosa, Juan Martín-Caballero, Juana M Flores, Maria T Diaz-Meco, Jorge Moscat, Manuel Serrano.   

Abstract

The proapoptotic protein encoded by Par4 (prostate apoptosis response 4) has been implicated in tumour suppression, particularly in the prostate. We report here that Par4-null mice are prone to develop tumours, both spontaneously and on carcinogenic treatment. The endometrium and prostate of Par4-null mice were particularly sensitive to the development of proliferative lesions. Most (80%) Par4-null females presented endometrial hyperplasia by 9 months of age, and a significant proportion (36%) developed endometrial adenocarcinomas after 1 year of age. Similarly, Par4-null males showed a high incidence of prostate hyperplasia and prostatic intraepithelial neoplasias, and were extraordinarily sensitive to testosterone-induced prostate hyperplasia. Finally, the uterus and prostate of young Par4-null mice have increased levels of the apoptosis inhibitor XIAP (X-chromosome-linked inhibitor of apoptosis), supporting the previously proposed function of Par4 as an inhibitor of the (zeta)PKC (atypical protein kinase)-NF-(kappa)B (nuclear factor-(kappa)B)-XIAP pathway. These data show that Par4 has an important role in tumour suppression, with a particular relevance in the endometrium and prostate.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15877079      PMCID: PMC1369092          DOI: 10.1038/sj.embor.7400421

Source DB:  PubMed          Journal:  EMBO Rep        ISSN: 1469-221X            Impact factor:   8.807


  27 in total

1.  Targeted disruption of the zetaPKC gene results in the impairment of the NF-kappaB pathway.

Authors:  M Leitges; L Sanz; P Martin; A Duran; U Braun; J F García; F Camacho; M T Diaz-Meco; P D Rennert; J Moscat
Journal:  Mol Cell       Date:  2001-10       Impact factor: 17.970

2.  Par-4, a proapoptotic gene, is regulated by NSAIDs in human colon carcinoma cells.

Authors:  Z Zhang; R N DuBois
Journal:  Gastroenterology       Date:  2000-06       Impact factor: 22.682

3.  Par4 is a coactivator for a splice isoform-specific transcriptional activation domain in WT1.

Authors:  D J Richard; V Schumacher; B Royer-Pokora; S G Roberts
Journal:  Genes Dev       Date:  2001-02-01       Impact factor: 11.361

4.  In lymphatic cells par-4 sensitizes to apoptosis by down-regulating bcl-2 and promoting disruption of mitochondrial membrane potential and caspase activation.

Authors:  Simone Boehrer; Kai U Chow; Florian Beske; Natasa Kukoc-Zivojnov; Elena Puccetti; Martin Ruthardt; Christine Baum; Vivek M Rangnekar; Dieter Hoelzer; Paris S Mitrou; Eckhart Weidmann
Journal:  Cancer Res       Date:  2002-03-15       Impact factor: 12.701

Review 5.  Cyclooxygenase-2: a novel target for cancer chemotherapy?

Authors:  W Dempke; C Rie; A Grothey; H J Schmoll
Journal:  J Cancer Res Clin Oncol       Date:  2001-07       Impact factor: 4.553

6.  The downregulation of the pro-apoptotic protein Par-4 is critical for Ras-induced survival and tumor progression.

Authors:  M Barradas; A Monjas; M T Diaz-Meco; M Serrano; J Moscat
Journal:  EMBO J       Date:  1999-11-15       Impact factor: 11.598

7.  Sex hormone-induced carcinogenesis in Rb-deficient prostate tissue.

Authors:  Y Wang; S W Hayward; A A Donjacour; P Young; T Jacks; J Sage; R Dahiya; R D Cardiff; M L Day; G R Cunha
Journal:  Cancer Res       Date:  2000-11-01       Impact factor: 12.701

Review 8.  Par-4: an emerging pivotal player in neuronal apoptosis and neurodegenerative disorders.

Authors:  M P Mattson; W Duan; S L Chan; S Camandola
Journal:  J Mol Neurosci       Date:  1999 Aug-Oct       Impact factor: 3.444

9.  Oncogenic Ras sensitizes cells to apoptosis by Par-4.

Authors:  A Nalca; S G Qiu; N El-Guendy; S Krishnan; V M Rangnekar
Journal:  J Biol Chem       Date:  1999-10-15       Impact factor: 5.157

10.  Dlk/ZIP kinase-induced apoptosis in human medulloblastoma cells: requirement of the mitochondrial apoptosis pathway.

Authors:  D Kögel; C Reimertz; P Mech; M Poppe; M C Frühwald; H Engemann; K H Scheidtmann; J H Prehn
Journal:  Br J Cancer       Date:  2001-11-30       Impact factor: 7.640

View more
  36 in total

Review 1.  PAR-4 as a possible new target for pancreatic cancer therapy.

Authors:  Asfar S Azmi; Philip A Philip; Syed F Zafar; Fazlul H Sarkar; Ramzi M Mohammad
Journal:  Expert Opin Ther Targets       Date:  2010-06       Impact factor: 6.902

Review 2.  Cancer-selective apoptotic effects of extracellular and intracellular Par-4.

Authors:  T Shrestha-Bhattarai; V M Rangnekar
Journal:  Oncogene       Date:  2010-05-03       Impact factor: 9.867

3.  Prostate apoptosis response-4 is expressed in normal cholangiocytes, is down-regulated in human cholangiocarcinoma, and promotes apoptosis of neoplastic cholangiocytes when induced pharmacologically.

Authors:  Antonio Franchitto; Alessia Torrice; Rossella Semeraro; Cristina Napoli; Gennaro Nuzzo; Felice Giuliante; Gianfranco Alpini; Guido Carpino; Pasquale Bartolomeo Berloco; Luciano Izzo; Antonio Bolognese; Paolo Onori; Anastasia Renzi; Alfredo Cantafora; Eugenio Gaudio; Domenico Alvaro
Journal:  Am J Pathol       Date:  2010-08-19       Impact factor: 4.307

4.  Par-4 binds to topoisomerase 1 and attenuates its DNA relaxation activity.

Authors:  Anindya Goswami; Shirley Qiu; Thomas S Dexheimer; Padhma Ranganathan; Ravshan Burikhanov; Yves Pommier; Vivek M Rangnekar
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

5.  The tumor suppressor Par-4 activates an extrinsic pathway for apoptosis.

Authors:  Ravshan Burikhanov; Yanming Zhao; Anindya Goswami; Shirley Qiu; Steven R Schwarze; Vivek M Rangnekar
Journal:  Cell       Date:  2009-07-23       Impact factor: 41.582

6.  Systemic Par-4 inhibits non-autochthonous tumor growth.

Authors:  Yanming Zhao; Ravshan Burikhanov; Jason Brandon; Shirley Qiu; Brent J Shelton; Brett Spear; Subbarao Bondada; Scott Bryson; Vivek M Rangnekar
Journal:  Cancer Biol Ther       Date:  2011-07-15       Impact factor: 4.742

Review 7.  The atypical PKCs in inflammation: NF-κB and beyond.

Authors:  Maria T Diaz-Meco; Jorge Moscat
Journal:  Immunol Rev       Date:  2012-03       Impact factor: 12.988

Review 8.  A journey beyond apoptosis: new enigma of controlling metastasis by pro-apoptotic Par-4.

Authors:  Reyaz Ur Rasool; Debasis Nayak; Souneek Chakraborty; Archana Katoch; Mir Mohd Faheem; Hina Amin; Anindya Goswami
Journal:  Clin Exp Metastasis       Date:  2016-08-27       Impact factor: 5.150

Review 9.  The Par-4/PTEN connection in tumor suppression.

Authors:  Maria T Diaz-Meco; Shadi Abu-Baker
Journal:  Cell Cycle       Date:  2009-08-29       Impact factor: 4.534

Review 10.  Of the atypical PKCs, Par-4 and p62: recent understandings of the biology and pathology of a PB1-dominated complex.

Authors:  J Moscat; M T Diaz-Meco; M W Wooten
Journal:  Cell Death Differ       Date:  2009-08-28       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.